Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $278.03 and traded as low as $265.00. Genmab A/S shares last traded at $266.07, with a volume of 180 shares traded.
Genmab A/S Trading Down 3.0 %
The business’s 50-day simple moving average is $268.04 and its 200-day simple moving average is $277.76.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.13 earnings per share for the quarter. Genmab A/S had a net margin of 29.06% and a return on equity of 20.60%. The business had revenue of $779.50 million during the quarter.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- Health Care Stocks Explained: Why You Might Want to Invest
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What is a Secondary Public Offering? What Investors Need to Know
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
